Company
Headquarters: Stockholm, Sweden
Employees: 66
$1.05 Billion
USD as of July 1, 2024
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.
| Last Financial Reports Date | Dec. 31, 2016 |
| Revenue TTM | €2.22 B |
| EBITDA | €308.7 M |
| Gross Profit TTM | €1.47 B |
| Profit Margin | 5.97% |
| Operating Margin | 9.18% |
| Quarterly Revenue Growth | 10.80% |
Calliditas Therapeutics AB (publ) has the following listings and related stock indices.
Stock: NASDAQ: CALT